Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

Chinese company acquires Cytovance Biologics

    Home Entrepreneur Chinese company acquires Cytovance Biologics
    NextPrevious

    Chinese company acquires Cytovance Biologics

    By admin | Entrepreneur, News | Comments are Closed | 25 August, 2015 | 0

    Chinese company acquires Oklahoma City firm Cytovance Biologics
    By Paul Monies
    Copyright © 2015 The Oklahoma Publishing Co.

    Cytovance Biologics Inc., an Oklahoma City-based pharmaceutical contract manufacturer, will be acquired by a unit of a Chinese company in a $206 million deal, the companies announced Monday.

    Hepalink USA, a subsidiary of Shenzhen Hepalink Pharmaceutical Co. Ltd., said the acquisition will allow it to accelerate Cytovance’s expansion plans.

    “We are excited about this transaction and what it means for Cytovance,” Darren Head, president and CEO of Cytovance, said in a statement. “This will expand our ability to develop and grow both our domestic and international businesses and to secure our current expansion plans in our Oklahoma City facilities. We do not anticipate any changes in how we currently do business. We will become part of a very successful company that shares our commitment to safety and quality.”

    Cytovance has 178 employees, all in Oklahoma City. The company’s management team will stay in place after the transaction closes.

    “We welcome and are honored to have Hepalink as the new owner of Cytovance,” said Dr. William Canfield, co-chair and founder of Cytovance. “They will be thrilled, as I have been, to work with Cytovance’s extraordinarily talented and capable team of professionals who have made a practice of exceeding customer expectations while building one of the world’s best companies in the biopharmaceutical contract manufacturing market.”

    Cytovance’s product lines are biologics, therapeutic proteins and antibodies made from either mammal cells or cells from bacteria. The company’s expansion plans include the addition of 5,000-liter and 10,000-liter mammalian reactors, which are used to grow proteins from mammal cells. It also expects to add 1,000-liter and 5,000-liter microbial fermentors, which are used to grow proteins from bacteria.

    Cytovance products are used by researchers for clinical trials to help find better vaccines and cures for diseases such as cancer, sickle cell anemia, asthma and gout.

    Hepalink said the addition of Cytovance will strengthen its contract development and manufacturing organization portfolio, which also includes Wisconsin-based Scientific Protein Laboratories LLC.

    “Hepalink will accelerate the realization of its strategy in the global macromolecule biopharmaceutical space,” Li Li, Hepalink’s chairman and CEO, said in a statement. “Cytovance will have the resources to expand its manufacturing capabilities, enhancing its ability in late-stage clinical drug production and commercial business. We are very impressed with Cytovance’s top-tier leadership team and will entrust this team to lead the future growth of the company.”

    Under the terms of the deal, Hepalink will acquire Cytovance for $205.68 million in cash, plus certain contingent payments. The transaction is expected to close in October following regulatory approval.

    Read the story at NewsOK.com

    Cytovance Biologics, Darren Head, Hepalink USA, Scientific Protein Laboratories LLC, Shenzhen Hepalink Pharmaceutical Co, William Canfield

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Media
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    100 S. Cincinnati Ave – 5th Floor, Suite 514
    Tulsa, OK 74103
    PHONE 918/582-5592
    Copyright 2022 i2E, Inc. | All Rights Reserved
    • About
    • Entrepreneurship
      • Venture Advisory Services
      • Love’s Entrepreneur’s Cup
      • ACT Tulsa
    • e3
    • Concept Fund
    • Portfolio
    • iMCI
    • ACT Tulsa
    • Contact
    i2E